Health‐related quality of life measured using QUALID (12–45, higher score indicates poorer quality of life) · people with dementia
1 finding from 1 review
Social functioning measured using MOSES, Withdrawn Behaviour subscale (8‐ 32, higher score indicates more severe withdrawn behaviour) · people with dementia
1 finding from 1 review
Behaviour · people with dementia
1 finding from 1 review
Agitation and irritability · people with dementia
1 finding from 1 review
Health‐related quality of life measured using QUALID (12–45, higher score indicates poorer quality of life) · people with dementia
1 finding from 1 review
ADL outcome · people with dementia
1 finding from 1 review
Physical functioning: self‐care ability measured using MOSES Self‐Care Functioning subscale (8–32, higher score indicates poorer function) · people with dementia
1 finding from 1 review
Adverse effects: astigmatism · people with recurrent corneal erosion syndrome without other corneal basement membrane dystrophy
1 finding from 1 review
Reading acuity · adults with low vision
1 finding from 1 review
Mean change from baseline in quality of life score (NEI VFQ‐25 instrument) · adults with low vision (people with AMD)
1 finding from 1 review
Hand function ‐ short term (less than 3 months) Grip function test scale of 0 to 80 points (higher score indicates better grip function) · rheumatoid arthritis of the hand
1 finding from 1 review
Hand function ‐ long term (12 months and beyond) Overall hand function subscale of the Michigan Hand Questionnaire, 0 to 100 (higher scores mean better hand function) · rheumatoid arthritis of the hand
2 findings from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · rheumatoid arthritis of the hand
2 findings from 1 review
Pain ‐ long term (12 months and beyond) Pain subscale of Michigan Hand Outcomes Questionnaire (0 to 100 points, higher score means more pain) · rheumatoid arthritis of the hand
1 finding from 1 review
Overall survival: higher‐dose WBRT vs control (3000 cGy/10 daily fractions)No. of participants: 846(4 RCTs) · patients with newly diagnosed multiple brain metastases
Altered WBRT fractionation schedules showed no clear difference in overall survival: higher‐dose WBRT vs control (3000 cGy/10 daily… compared with WBRT control (moderate certainty).
1 finding from 1 review
HR 0.97 [0.83, 1.12]
Studies not reported
Moderate
Neurological function improvement: higher‐dose WBRT vs control dose WBRT (3000 cGy/10 fractions)No. of participants: 1480(4 RCTs) · patients with newly diagnosed multiple brain metastases
Altered WBRT fractionation schedules showed no clear difference in neurological function improvement: higher‐dose WBRT vs control dose… compared with WBRT control: neurological function improvement (moderate certainty).
1 finding from 1 review
OR 1.14 [0.92, 1.42]
Studies not reported
Moderate
Physical quality of life · clinical diagnosis of depression
1 finding from 1 review
Quality of life (emotional) · clinical diagnosis of depression
1 finding from 1 review
Physical quality of life · clinical diagnosis of depression
1 finding from 1 review
Quality of life (emotional) · clinical diagnosis of depression
1 finding from 1 review